FS, OS double positive! Baili Tianheng (688506.SH) Iza-bren treatment for advanced esophageal squamous cell carcinoma stage III clinical trial reached the main endpoint in the middle of the analysis.

According to the WiseFinance APP, recently, BaiLi TianHeng (688506.SH) announced that its independently developed EGFRHER3 bispecific ADC (iza-bren), which is the world's first and only new concept entering Phase III clinical trials, has achieved dual positive primary endpoints of progression-free survival (PFS) and overall survival (OS) in the Phase III clinical trial for squamous cell carcinoma of the esophagus, as judged by an independent data monitoring committee. The indication is: recurrent or metastatic squamous cell carcinoma of the esophagus that has previously failed treatment with PD-1/PD-L1 monotherapy combined with platinum-based chemotherapy. This is the first Phase III clinical study in the world to achieve dual positive results of PFS/OS for an ADC drug in the treatment of esophageal cancer.